Timolumab

N/A

Report date: 2023/10/23 20:07:51

Base Information

Drug NameTimolumab
Drug Alias NameSI-3106BTT-1023
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunomodulatorsAmine oxidase, copper containing inhibitors
TargetsAmine oxidase, copper containing
Therapy Area/IndicationsPlaque psoriasisCholangitis, SclerosingArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaGermanyUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiotie
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsPlaque psoriasisCholangitis, SclerosingArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A